Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cocrystal Pharma, Inc. - Common Stock
(NQ:
COCP
)
1.520
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cocrystal Pharma, Inc. - Common Stock
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
March 14, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Sciences Investor Forum Agenda Announced for March 13th
March 12, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
August 15, 2024
Via
ACCESSWIRE
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
March 05, 2024
Via
ACCESSWIRE
Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast
January 23, 2023
Phoenix, Arizona--(Newsfile Corp. - January 23, 2023) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("Cocrystal," "Cocrystal...
Via
Newsfile
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
December 01, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
November 17, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
November 14, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma to Participate in Two Investor Conferences in November
November 02, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza
November 01, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
October 26, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma to Present at the LD Micro Main Event XV
October 19, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022
October 13, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19
October 11, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
October 05, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split
October 03, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast
August 03, 2022
Phoenix, Arizona--(Newsfile Corp. - August 3, 2022) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("the Company"),...
Via
Newsfile
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
August 19, 2021
Via
FinancialNewsMedia
California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers
August 03, 2021
Via
FinancialNewsMedia
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
